Management of acromegaly in Latin America: expert panel recommendations
Authors:
Open Access
- 31 October 2009
- journal article
- review article
- Published by Springer Nature in Pituitary
- Vol. 13 (2) , 168-175
Abstract
Although there are international guidelines orienting physicians on how to manage patients with acromegaly, such guidelines should be adapted for use in distinct regions of the world. A panel of neuroendocrinologists convened in Mexico City in August of 2007 to discuss specific considerations in Latin America. Of major discussion was the laboratory evaluation of acromegaly, which requires the use of appropriate tests and the adoption of local institutional standards. As a general rule to ensure diagnosis, the patient’s GH level during an oral glucose tolerance test and IGF-1 level should be evaluated. Furthermore, to guide treatment decisions, both GH and IGF-1 assessments are required. The treatment of patients with acromegaly in Latin America is influenced by local issues of cost, availability and expertise of pituitary neurosurgeons, which should dictate therapeutic choices. Such treatment has undergone profound changes because of the introduction of effective medical interventions that may be used after surgical debulking or as first-line medical therapy in selected cases. Surgical resection remains the mainstay of therapy for small pituitary adenomas (microadenomas), potentially resectable macroadenomas and invasive adenomas causing visual defects. Radiotherapy may be indicated in selected cases when no disease control is achieved despite optimal surgical debulking and medical therapy, when there is no access to somatostatin analogues, or when local issues of cost preclude other therapies. Since not all the diagnostic tools and treatment options are available in all Latin American countries, physicians need to adapt their clinical management decisions to the available local resources and therapeutic options.Keywords
This publication has 83 references indexed in Scilit:
- GH and IGF‐I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatmentClinical Endocrinology, 2008
- Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegalyEuropean Journal of Endocrinology, 2007
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trialClinical Endocrinology, 2006
- First‐line octreotide‐LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trialClinical Endocrinology, 2006
- Treatment of acromegaly with octreotide‐LAR: extensive experience in a Brazilian institutionClinical Endocrinology, 2005
- Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin statusClinical Endocrinology, 2004
- Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2000
- Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 1998
- Cabergoline in the Treatment of Acromegaly: A Study in 64 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1998